CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer

Status Recruiting

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with Itraconazole in patients with locally adcvanced esophageal squamous cancer

Clinical Trial Description

Esophageal cancer is one of the most lethal malignancies. Esophageal squamous cell carcinoma (ESCC) is the predominant type in China, accounting for over 90% of all esophageal cancer. Concurrent chemoradiation therapy (CCRT) remains the standard therapy of locally advanced ESCC. However, the outcome remains poor.

The aberrant activation of Hedgehog (HH) signaling is associated with a variety of human malignancies. Previous studies found that the reactivation of HH pathway occurs in 60% of esophageal cancer. Targeting the Hh pathway for cancer therapy was expected to work wonders in Hh-dependent cancers. Itraconazole, an antifungal agent, has been shown to inhibit the Hh and AKT signaling pathways.

The aim of our study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with Itraconazole in patients with locally adcvanced esophageal squamous cancer ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04481100
Study type	Interventional
Source	Hangzhou Cancer Hospital
Contact	Shixiu Wu, phD
Phone	86-755-66618168
Email	wushixiu@medmail.com.cn
Status	Recruiting
Phase	Phase 2
Start date	October 1, 2020
Completion date	July 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06056336` - Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma	Phase 2
Suspended	`NCT04084158` - A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.	Phase 2
Recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT05561699` - Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer	N/A
Active, not recruiting	`NCT04543617` - A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy	Phase 3
Recruiting	`NCT06190782` - Local Therapy for Oligometastatic Esophageal Squamous Cell Cancer Patients Treated With PD-1 Inhibitor: a Prospective, Randomized, Phase III Clinical Trial.	Phase 3
Completed	`NCT05557955` - Identification of Breath Biomarkers in Esophageal Cancer
Recruiting	`NCT04045496` - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04584008` - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics	N/A
Not yet recruiting	`NCT03766178` - Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT02913066` - S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma	Phase 2
Completed	`NCT02399306` - Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma	Phase 3
Completed	`NCT01605305` - Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer	Phase 2
Not yet recruiting	`NCT05552651` - Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT05520619` - Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)	Phase 2
Terminated	`NCT03251417` - Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT05990231` - Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy	Phase 2
Recruiting	`NCT04644250` - Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Completed	`NCT02916511` - Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma	Phase 2
Terminated	`NCT04032704` - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	Phase 2